RIDDLE&CODE
31.5.2022 10:17:11 CEST | Business Wire | Press release
RIDDLE&CODE is now a member of the Catena-X Automotive Network e.V, an automotive association formed by leading industry players. Both Catena-X and RIDDLE&CODE aim to establish a decentralised data ecosystem through tokenization, tamper-proof identities, and digital twins of machines, vehicles and their components.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005104/en/
Catena-X is dedicated to developing an open, scalable industrial ecosystem that provides a data space and secure processes for all contributors across the automotive industry. The idea is to create a network where manufacturers, suppliers and all those involved in the value chain can participate in creating consistent means for data sharing and standardisation.
About the Catena-X Automotive Network
The Catena-X ecosystem consists of a consortium of 28 members from the automotive, business and scientific communities. It is funded by the German Ministry of Economic Affairs and Climate Action 0. The automotive industry launched a Public Association in 2021, which includes companies that actively want to shape the Catena-X ecosystem l. RIDDLE&CODE has become a member of the Association.
The strategic goal of Catena-X is to implement a standardised ecosystem across the automotive industry. This incentive was initiated by German companies in the automotive sector. It will then be adopted by the entirety of the European automobile industry and beyond.
While the Gaia-X infrastructure initiative aims to provide sovereign access to data via shared services for various industries, Catena-X specifically caters to the automotive industry. Data monetisation and implementation of token-based ecosystems are essential parts of the project. This has been done to drive these industry segments in the right direction of the environmental, social and governance (ESG) goals on different levels.
RIDDLE&CODE’s reasons to join
RIDDLE&CODE will contribute to the Catena-X network by bringing in its expertise in blockchain frameworks. This has been demonstrated through projects such as the European Blockchain Services Infrastructure PCP. RIDDLE&CODE, along with other partners, introduced a truly European architecture dubbed ZENBRIDGE. The project is supported by the European Commission.
Our ambition is to accelerate the move towards a transparent automotive ecosystem where data can be shared easily without facing obstacles from different proprietary infrastructures. Since its inception, RIDDLE&CODE has tackled these challenges.
"We are joining the association and partners to add our Trusted Car Wallet and Distributed Ledger Technology (DLT) software stack to the upcoming connected car data standards," said Minh Cao, Director of Mobility & Automotive at RIDDLE&CODE. "Our focus is to guarantee robust data directly from vehicles, providing trust and transparency to enable automation driven by AI and confidential edge computing."
"The objective is,” he continued, “to build a professional, standardised and modular toolchain for original equipment manufacturers (OEM) developers in the automotive ACES (Automated, Connected, Electric and Shared) and micromobility space that enables rapid prototyping of blockchain-based mobility solutions that leverage cryptographic techniques for data attestation and integration: tokenomics, decentralised data markets & data-rich vehicle networks. The RIDDLE&CODE toolchain will reduce complexity and simplify experimentation so that users can focus on building value-added business models whilst protecting manufacturers' intellectual property (IP)."
Catena-X includes major market shareholders such as BMW AG, Deutsche Telekom AG, Robert Bosch GmbH, Siemens AG, Mercedes-Benz AG and many more. Our membership will include exchanging ideas and technologies to further enrich this initiative.
About RIDDLE&CODE
RIDDLE&CODE is Europe’s leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About the Catena-X Automotive Network
Catena-X sees itself as a rapidly scalable, interoperable ecosystem in which all contributors in the automotive value chain can participate equally. The goal: to provide room for the creation, operation and collaborative use of end-to-end data chains along the entire automotive value chain. As of May 1st 2022, the Catena-X Automotive Network e.V. has 96 members who are active as providers and users in the automotive value chain and cover a wide range of company sizes.
More information: www.catena-x.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005104/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom